Related Experiment Video
Updated: Mar 31, 2026
Isolation, Enrichment, and Maintenance of Medulloblastoma Stem Cells
Published on: September 1, 2010
Characterization of anaplastic lymphoma kinase-positive medulloblastomas
Benedict Yan1, Chik Hong Kuick2, Malcolm Lim2
1Department of Laboratory Medicine, Molecular Diagnosis Centre, National University Hospital, National University Health System, 5 Lower Kent Ridge Road, Singapore 119074, Singapore.
Abstract:
Medulloblastomas are the most common pediatric malignant primary brain tumor. To our knowledge, there are no known critical and druggable tyrosine kinases in medulloblastomas, precluding the use of established tyrosine kinase inhibitors that have shown efficacy in other tumor types. We studied the expression of anaplastic lymphoma kinase (ALK), a well-characterized tyrosine kinase and drug target, in a cohort of medulloblastomas by immunohistochemistry, and identified three ALK-positive cases. Mutational analyses did not reveal a definite underlying genetic mechanism for the ALK expression, although one of the cases showed increased ALK copy number. Our findings have clinical implications and warrant further pharmacological and functional studies, as well as evaluation in larger patient cohorts, to fully characterize the value of ALK as a prognostic and predictive therapeutic marker in medulloblastomas.
Insights
Anaplastic lymphoma kinase (ALK) was found in three pediatric medulloblastoma cases, suggesting it could be a potential therapeutic target. Further research is needed to confirm ALK
Area of Science:
- Pediatric neuro-oncology
- Molecular biology
- Cancer genetics
Background:
- Medulloblastomas are the most common malignant pediatric brain tumors.
- No critical druggable tyrosine kinases are currently known in medulloblastomas.
- This limits treatment options with tyrosine kinase inhibitors.
Purpose of the Study:
- To investigate the expression of anaplastic lymphoma kinase (ALK) in medulloblastomas.
- To identify potential therapeutic targets for this pediatric brain tumor.
- To explore ALK as a prognostic and predictive marker.
Main Methods:
- Immunohistochemistry was used to detect ALK expression in a cohort of medulloblastomas.
- Mutational analyses were performed to identify genetic mechanisms of ALK expression.
- ALK copy number was assessed.
Main Results:
- Three cases of anaplastic lymphoma kinase (ALK)-positive medulloblastomas were identified.
- Mutational analyses did not reveal a clear genetic cause for ALK expression.
- One case showed an increased ALK copy number.
Conclusions:
- Anaplastic lymphoma kinase (ALK) is expressed in a subset of medulloblastomas.
- ALK represents a potential therapeutic target and prognostic marker.
- Further studies are warranted to validate ALK's role in medulloblastoma treatment.
